Early attempts at using BRAF inhibitors such as vemurafenib, which has been successful in treating BRAF-mutant melanoma, showed limited efficacy in CRC, mostly due to rapid reactivation of EGFR signaling, a compensatory mechanism that allows cancer cells to bypass BRAF inhibition [50]. This evidence concerns the gene EGFR and cancer.